TPD52 and cancer: Through a literature review, it is also revealed that KLF3, TPD52, PKCε, and miR-124 interact with different downstream signaling molecules of these pathways in different cancers and lead to cancer proliferation, stage progression and metastasis, and drug resistance [10–15].